MediWound

MediWound is a global leader in pharmaceutical manufacturing, specializing in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Committed to replacing existing standards of care, MediWound develops, produces, and commercializes innovative biologics designed to improve patient experiences and outcomes while reducing costs and unnecessary surgeries.

Located at HaYarkon 42, Yavne, 8122745, IL, MediWound's pioneering work includes NexoBrid®, an FDA-approved orphan biologic for eschar removal in severe burns, offering a non-surgical alternative that minimizes complications. The company's robust R&D pipeline features EscharEx®, a Phase III-ready biologic for chronic wound debridement, poised to significantly improve upon existing treatments.

MediWound continues to drive advancements in tissue repair through innovative research and development. To learn more about how MediWound can elevate your product offerings, we invite the company’s management to create a customized and exclusive company showcase and product listing on our platform.